Back to Search Start Over

Antiplatelet drugs and liver fibrosis.

Authors :
ZHAO Xin
LI Hui
DENG Xiuxiu
TAO Yujing
Source :
Journal of Practical Medicine / Shiyong Yixue Zazhi; 4/25/2024, Vol. 40 Issue 8, p1083-1087, 5p
Publication Year :
2024

Abstract

The essence of hepatic fibrosis is the imbalance of the formation and degradation of extracellular matrix in the liver tissue. Hepatic fibrosis is a necessary stage for the progression of various chronic liver diseases to cirrhosis. Early inhibition of the occurrence and development of hepatic fibrosis is very important in the treatment of liver diseases. Platelets release a variety of cytokines, which promote hepatocyte proliferation and liver parenchyma regeneration while activating endothelial cells, inducing leukocyte recruitment, aggravating microvascular dysfunction, and participating in the process of liver fibrosis. In this paper, the research progress of antiplatelet drugs in hepatic fibrosis is reviewed, in order to provide new diagnosis and treatment ideas for hepatic fibrosis. [ABSTRACT FROM AUTHOR]

Details

Language :
Chinese
ISSN :
10065725
Volume :
40
Issue :
8
Database :
Complementary Index
Journal :
Journal of Practical Medicine / Shiyong Yixue Zazhi
Publication Type :
Academic Journal
Accession number :
176819439
Full Text :
https://doi.org/10.3969/j.issn.1006-5725.2024.08.011